Evidence map›Paper›PMID 31279695›Full record

ArticleCytotherapy2019

Generation of Zika virus-specific T cells from seropositive and virus-naïve donors for potential use as an autologous or "off-the-shelf" immunotherapeutic.

Ryo Hanajiri, Gelina M Sani, Patrick J Hanley, Cassia G Silveira, Esper G Kallas, Michael D Keller, Catherine M Bollard

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Cell therapies for viral diseases: a new frontier.Seminars in immunopathology · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ryo HanajiriCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Gelina M SaniCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Patrick J HanleyCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA.
Cassia G SilveiraDepartment of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, São Paulo, Brazil.
Esper G KallasDepartment of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, São Paulo, Brazil.
Michael D KellerCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA; Division of Allergy and Immunology, Children's National Health System, Washington, DC, USA.
Catherine M BollardCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Health System, Washington, DC, USA. Electronic address: cbollard@childrensnational.org.
Children's National · USUniversidade de São Paulo · BRGeorge Washington University · US

Funding

PR1-specific CB T cells for Patients with Myeloid MalignanciesP01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOLLARD, CATHERINE M., SHPALL, ELIZABETH J · 2011 to 2022
$24.4M
Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency DisordersK23HL136783 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI KELLER, MICHAEL DANIEL · 2017 to 2019
$614k
NCI NIH HHS P01 CA148600NHLBI NIH HHS K23 HL136783
6 · The paper itself

Abstract

backgroundZika virus (ZIKV) infection can cause severe birth defects in newborns with no effective currently available treatment. Adoptive transfer of virus-specific T cells has proven to be safe and effective for the prevention or treatment of many viral infections, and could represent a novel treatment approach for patients with ZIKV infection. However, extending this strategy to the ZIKV setting has been hampered by limited data on immunogenic T-cell antigens within ZIKV. Hence, we have generated ZIKV-specific T cells and characterized the cellular immune responses against ZIKV antigens.

methodsT-cell products were generated from peripheral blood of ZIKV-exposed donors, ZIKV-naive adult donors and umbilical cord blood by stimulation with pentadecamer (15mer) overlapping peptide libraries spanning four ZIKV polyproteins (C, M, E and NS1) using a Good Manufacturing Practice-compliant protocol.

resultsWe successfully generated T cells targeting ZIKV antigens with clinically relevant numbers. The ex vivo-expanded T cells comprised both CD4 DISCUSSION: Our findings demonstrate that it is feasible to generate potent ZIKV-specific T cells from a variety of cell sources including virus naïve donors for future clinical use in an "off-the-shelf" setting.

Indexed as

Adoptive TransferAdultAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEpitope MappingEpitopesFetal BloodHumansImmunity, CellularInfant, NewbornZika VirusZika Virus InfectionAntigens, ViralEpitopescord bloodepitope mappingGood Manufacturing PracticeimmunotherapyT lymphocytesZika virus

Identifiers

PMID31279695
PMCPMC6744970
OpenAlexW2953957212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.